Noah AI Industry News

Delivers real-time biopharma news and signals — powered by AI, curated for professionals.

AI-Powered Chart Review Startup Charta Health Secures $22M in Series A Funding

AI-Powered Chart Review Startup Charta Health Secures $22M in Series A Funding

Charta Health, a one-year-old startup specializing in AI-powered medical billing and coding optimization, has raised $22 million in series A funding. This latest investment brings the company's total funding for the year to $30 million, following an $8.1 million seed round in March.

NoahAI News7/25/2025
Leadership Shifts and Strategic Moves Reshape Pharmaceutical Landscape

Leadership Shifts and Strategic Moves Reshape Pharmaceutical Landscape

In a week marked by significant executive appointments and strategic realignments, the pharmaceutical industry continues to evolve rapidly. From merger-driven leadership changes to expanded executive teams and clinical advancements, companies across the sector are positioning themselves for future growth and innovation.

NoahAI News7/25/2025
NeuroFlow and ChristianaCare Partner to Enhance Maternal Mental Health Screening

NeuroFlow and ChristianaCare Partner to Enhance Maternal Mental Health Screening

In a significant move to address the critical issue of maternal mental health, behavioral health technology company NeuroFlow has joined forces with ChristianaCare, a Delaware-based health system. This collaboration aims to provide comprehensive mental health screening and support for pregnant and postpartum patients across ChristianaCare's network.

NoahAI News7/25/2025
Eli Lilly Inks $856M Deal with Gate Bioscience for Novel Small-Molecule Drug Class

Eli Lilly Inks $856M Deal with Gate Bioscience for Novel Small-Molecule Drug Class

Eli Lilly has entered into a significant partnership with California-based biotech Gate Bioscience, potentially worth up to $856 million, to develop a new class of small-molecule drugs. The collaboration, announced on July 24, 2025, aims to leverage Gate's proprietary discovery engine to identify and develop "molecular gates" - selective small-molecule drugs designed to eradicate harmful extracellular proteins.

NoahAI News7/25/2025
Brandon Capital Raises Record-Breaking $290M for Life Sciences Fund

Brandon Capital Raises Record-Breaking $290M for Life Sciences Fund

Australian venture capital firm Brandon Capital has announced the closure of its largest fund to date, raising A$439 million (approximately $290 million) for the sixth Brandon BioCatalyst Fund. This significant influx of capital aims to support fast-growing companies with strong commercial potential in the life sciences sector.

NoahAI News7/25/2025
AstraZeneca's Gefurulimab Shows Promise in Phase III Trial for Myasthenia Gravis

AstraZeneca's Gefurulimab Shows Promise in Phase III Trial for Myasthenia Gravis

AstraZeneca has announced positive results from its Phase III PREVAIL trial for gefurulimab, a novel nanobody treatment for generalized myasthenia gravis (gMG). The investigational therapy met all primary and secondary endpoints, marking a significant advancement in the treatment of this rare autoimmune disorder.

NoahAI News7/24/2025
Novartis Secures $1B+ Drug Discovery Deal with Matchpoint Therapeutics

Novartis Secures $1B+ Drug Discovery Deal with Matchpoint Therapeutics

Novartis has entered into a significant drug discovery collaboration with Matchpoint Therapeutics, potentially worth over $1 billion, to develop new treatments for inflammatory diseases. The deal, announced on Thursday, centers around Matchpoint's Advanced Covalent Exploration (ACE) platform and aims to identify novel oral inhibitors targeting an undisclosed transcription factor.

NoahAI News7/24/2025
Biopharma Layoffs: Unconventional Notifications Raise Concerns in Industry

Biopharma Layoffs: Unconventional Notifications Raise Concerns in Industry

In a startling revelation, numerous biopharma professionals have reported unusual and often disconcerting methods by which they were informed of their job terminations. These accounts shed light on the communication challenges faced by companies during workforce reductions, highlighting a need for more sensitive and professional approaches to layoffs in the pharmaceutical industry.

NoahAI News7/24/2025
Major Biopharma Layoffs in 2025: Tessera and Generate Downsize

Major Biopharma Layoffs in 2025: Tessera and Generate Downsize

Pharmaceutical Industry Layoffs Continue Amid Restructuring and Pipeline ShiftsThe pharmaceutical and biotech sectors continue to face significant workforce reductions as companies across the industry announce layoffs, restructuring initiatives, and strategic pivots. Recent weeks have seen a wave of job cuts affecting thousands of employees, with several major players citing the need to streamline operations, extend cash runways, and refocus on key pipeline assets.

NoahAI News7/24/2025
FDA Delays Decision on GSK's Blenrep, Extending Review Period for Multiple Myeloma Treatment

FDA Delays Decision on GSK's Blenrep, Extending Review Period for Multiple Myeloma Treatment

The U.S. Food and Drug Administration (FDA) has extended its review period for GSK's antibody-drug conjugate Blenrep, pushing the target decision date from July 23 to October 23, 2025. This delay comes as GSK seeks to reintroduce Blenrep to the U.S. market for the second-line treatment of relapsed or refractory multiple myeloma.

NoahAI News7/24/2025
Genentech Restructures Workforce Amid Strategic Shifts in Pharmaceutical Industry

Genentech Restructures Workforce Amid Strategic Shifts in Pharmaceutical Industry

Genentech, a subsidiary of Roche, has announced another round of layoffs at its South San Francisco headquarters, with 87 employees set to be terminated on September 15. This decision comes on the heels of a previous workforce reduction just last month, which saw 143 employees let go from the same location.

NoahAI News7/24/2025
Roche Discontinues Early-Stage Obesity Drug, Maintains Confidence in Portfolio

Roche Discontinues Early-Stage Obesity Drug, Maintains Confidence in Portfolio

Roche, the Swiss pharmaceutical giant, has announced the discontinuation of CT-173, an early-stage obesity treatment, citing a lack of competitiveness. The decision was revealed during the company's second-quarter earnings call, where executives also highlighted strong financial performance and optimism about their broader obesity pipeline.

NoahAI News7/24/2025
«1...567...67»